ASCO |
American Society of Clinical Oncology |
ATF3 |
Activating transcription factor 3 |
BIPN |
Bortezomib-induced peripheral neuropathy |
CCL |
CC chemokine ligand |
CIPN |
Chemotherapy-induced peripheral neuropathy |
Cmax
|
Maximum blood concentration |
CNS |
Central nervous system |
DRG |
Dorsal root ganglia |
ER |
Endoplasmic reticulum |
ERK |
Extracellular signal-regulated protein kinase |
FDA |
the US Food and Drug Administration |
GFAP |
Glial fibrillary acidic protein |
GLAST |
Glutamate/aspartate transporter |
IENF |
Intraepidermal nerve fiber |
IL |
Interleukin |
JNK |
c-Jun N-terminal kinase |
MAPK |
Mitogen-activated protein kinase |
mEPSCs |
Miniature excitatory postsynaptic currents |
NAD+
|
Nicotinamide adenine dinucleotide |
NF-κB |
Nuclear factor kappa-light-chain-enhancer of activated B cells |
NLRP3 |
NOD-like receptor family pyrin domain containing 3 |
PNS |
Peripheral nervous system |
PKC |
Protein kinase C |
ROS |
Reactive oxygen species |
SARM1 |
Sterile alpha and toll/interleukin-1 receptor motif-containing 1 |
S1P |
Sphingosine-1-phosphate |
S1PR |
Sphingosine-1-phosphate receptor |
STAT3 |
Signal transducer and activator of transcription-3 |
TNF-α |
Tumor necrosis factor alpha |
TRPA1 |
Transient receptor potential ankyrin 1 |